FindTrial
Sign In

A retrospective study of Evion LC in patients with muscle cramps and spasm

A retrospective, electronic health records study of patients prescribed with Evion® LC. - EROS

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/03/051225
Enrollment
2000
Registered
2023-03-31
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M60-M63- Disorders of muscles

Interventions

None listed

Sponsors

Procter & Gamble Health Limited (PGHL)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Electronic medical records (EMR) of male or female adult patients 18 years and above of age, who were prescribed Evion® LC, will be selected.

Exclusion criteria

Exclusion criteria: EMR with any incomplete key data points will be excluded.

Design outcomes

Primary

MeasureTime frame
The percentage of patients for whom there is evidence of improvement in muscle cramps following prescription of Evion® LCTimepoint: Not applicable—

Secondary

MeasureTime frame
1. The relative frequency of Evion® LC prescriptions as a function of dose and daily dose frequency, e.g. once daily, twice daily, etc. 2. The mean period of time that patients dose Evion® LC 3. The mean age of patients prescribed Evion® LC 4. The percentage of males and females prescribed Evion® LC 5. The relative frequency of health conditions among patients prescribed Evion® LC. Additional secondary endpoints may be explored post hoc, if required.Timepoint: baseline, 4months—

Countries

India

Contacts

Public ContactDr Poonam Sule

Procter and Gamble Health Limited

sule.p@pg.com0091-9619207436

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026